Medical device compliance is not optional — it is foundational to safe patient care.
In the United States, all traction and non-surgical spinal decompression systems are regulated by the U.S. Food and Drug Administration (FDA) as Class II medical devices. That classification carries specific requirements for identification, listing, maintenance, servicing, and traceability.
Clinics offering IDD Therapy® using the Accu-SPINA® System operate within this federal regulatory framework. Understanding how FDA device classification, Unique Device Identification (UDI), and the Global Unique Device Identification Database (GUDID) apply to spinal decompression equipment is essential for:
According to the FDA’s official medical device regulation overview, Class II devices are subject to “special controls” in addition to general regulatory requirements to provide reasonable assurance of safety and effectiveness.
Additionally, the FDA’s UDI system was implemented to improve device traceability, post-market surveillance, and recall efficiency across healthcare settings.
With that regulatory foundation in mind, it is important to understand how these requirements specifically apply to spinal decompression and traction equipment used in clinical settings.
Here we will provide a clear, evidence-based explanation of:
All traction and non-surgical spinal decompression devices — regardless of brand or marketing terminology — are regulated by the FDA as Class II medical devices. Class II designation means the device is considered moderate risk and must comply with:
This classification applies universally across the industry.
For clinics, compliance does not mean filing documents with the FDA. It means ensuring the equipment used in patient care is properly classified, properly identified, and maintained according to manufacturer and regulatory standards.
The Accu-SPINA® System, manufactured by North American Medical (NAM), is an FDA-regulated Class II medical device. When the FDA’s UDI regulation became law, NAM fulfilled its regulatory obligations by filing the Accu-SPINA® System with the FDA’s Global Unique Device Identification Database (GUDID) in 2016.
Clinics using an authentic Accu-SPINA® System supplied through proper channels are therefore operating with equipment that has already met federal UDI and listing requirements.
Clinics may independently verify any device in the FDA’s public GUDID database:
https://accessgudid.nlm.nih.gov/
When your clinic uses an FDA-listed Accu-SPINA® System:
These systems exist to enhance transparency and protect patients.
Compliance risk most often arises not from manufacturer-supplied equipment, but from devices acquired through third-party or used-equipment resellers.
Under FDA regulations, entities that manufacture, relabel, or remanufacture medical devices must be properly registered and listed. Many third-party resellers of used spinal decompression or traction equipment do not meet these regulatory criteria. In some cases, resellers:
When equipment is acquired outside the original manufacturer’s distribution and support structure, the responsibility to verify compliance shifts directly to the clinic. This is why integrity matters when it comes to where the equipment comes from.
FDA oversight ultimately places responsibility on healthcare providers to ensure that medical devices used in patient care are properly regulated. When purchasing equipment — especially used equipment — clinics should verify:
If a reseller cannot demonstrate proper FDA listing or GUDID registration, the compliance exposure rests with the clinic. Clinics can verify devices directly at: https://accessgudid.nlm.nih.gov/
FDA guidance distinguishes between routine servicing and remanufacturing. Routine servicing maintains the device within its original performance specifications. Remanufacturing occurs when modifications significantly change performance, safety characteristics, or intended use.
Unapproved parts, altered software, or unauthorized mechanical adjustments may unintentionally shift a device into remanufactured status, potentially requiring new regulatory clearance. Best practices for clinics include:
These steps protect patient safety and preserve regulatory alignment.
Documentation supports both regulatory compliance and professional accountability.
Clinics should maintain:
In a regulated healthcare environment, documentation, traceability, and manufacturer accountability are not optional — they are integral to responsible patient care.
Compliance extends beyond the device to its clinical application. Clinics providing IDD Therapy® should ensure:
Proper training reinforces both safety and clinical consistency.
Even FDA-regulated equipment must be used properly. Provider training ensures:
North American Medical has fulfilled its obligations by ensuring that Accu-SPINA® Systems are properly classified as Class II medical devices and listed in the FDA’s GUDID database. From there, responsibility shifts to clinics to:
In regulated healthcare environments, integrity is demonstrated through traceability, documentation, and adherence to manufacturer and federal standards.
FDA compliance is not an administrative burden — it is part of delivering safe, responsible, and trustworthy patient care.